Literature DB >> 9794439

Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration.

Y Akwa1, D E Hassett, M L Eloranta, K Sandberg, E Masliah, H Powell, J L Whitton, F E Bloom, I L Campbell.   

Abstract

Type I IFNs, which include IFN-alpha, appear to have complex and broad-ranging actions in the central nervous system (CNS) that may result in protection or injury. To better understand these issues, we generated transgenic mice that produce IFN-alpha1 chronically from astrocytes. These glial fibrillary acidic protein-IFN-alpha transgenic mice developed a progressive inflammatory encephalopathy, with marked calcium mineralization, meninoencephalitis, gliosis, and neurodegeneration. Many features of this murine encephalopathy resembled those found in certain human encephalopathies of unknown etiology; these diseases, exemplified by Aicardi-Goutières syndrome and some viral encephalopathies, show increased intrathecal production of IFN-alpha. Our data suggest that IFN-alpha overproduction may be the primary factor initiating these human diseases. Following intracerebral infection with lymphocytic choriomeningitis virus, glial fibrillary acidic protein-IFN-alpha mice had significantly increased survival rates associated with markedly reduced virus titers and immune pathology in the brain but normal peripheral CTL responses. Therefore, the production of IFN-alpha in the CNS can be a two-edged sword that on the one hand confers protection against a lethal viral infection but on the other causes significant injury to the brain. These transgenic mice provide a novel animal model in which to further evaluate the mechanisms that underlie the diverse actions of type I IFNs in the intact CNS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794439

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  92 in total

1.  STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system.

Authors:  Jianping Wang; Robert D Schreiber; Iain L Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

2.  Genome-wide detection of tissue-specific alternative splicing in the human transcriptome.

Authors:  Qiang Xu; Barmak Modrek; Christopher Lee
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

Review 3.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

4.  Herpes simplex virus type 1 induction of chemokine production is unrelated to viral load in the cornea but not in the nervous system.

Authors:  Daniel J J Carr; Iain L Campbell
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

5.  Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro.

Authors:  V C Asensio; J Maier; R Milner; K Boztug; C Kincaid; M Moulard; C Phillipson; K Lindsley; T Krucker; H S Fox; I L Campbell
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

7.  Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease.

Authors:  Gillian I Rice; Naoki Kitabayashi; Magalie Barth; Tracy A Briggs; Annabel C E Burton; Maria Luisa Carpanelli; Alfredo M Cerisola; Cindy Colson; Russell C Dale; Federica Rachele Danti; Niklas Darin; Begoña De Azua; Valentina De Giorgis; Christian G L De Goede; Isabelle Desguerre; Corinne De Laet; Atieh Eslahi; Michael C Fahey; Penny Fallon; Alex Fay; Elisa Fazzi; Mark P Gorman; Nirmala Rani Gowrinathan; Marie Hully; Manju A Kurian; Nicolas Leboucq; Jean-Pierre S-M Lin; Matthew A Lines; Soe S Mar; Reza Maroofian; Laura Martí-Sanchez; Gary McCullagh; Majid Mojarrad; Vinodh Narayanan; Simona Orcesi; Juan Dario Ortigoza-Escobar; Belén Pérez-Dueñas; Florence Petit; Keri M Ramsey; Magnhild Rasmussen; François Rivier; Pilar Rodríguez-Pombo; Agathe Roubertie; Tommy I Stödberg; Mehran Beiraghi Toosi; Annick Toutain; Florence Uettwiller; Nicole Ulrick; Adeline Vanderver; Amy Waldman; John H Livingston; Yanick J Crow
Journal:  Neuropediatrics       Date:  2017-04-10       Impact factor: 1.947

8.  Cerebral expression of interleukin-12 induces neurological disease via differential pathways and recruits antigen-specific T cells in virus-infected mice.

Authors:  Markus Hofer; Jürgen Hausmann; Peter Staeheli; Axel Pagenstecher
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9.

Authors:  Markus J Hofer; Wen Li; Sue Ling Lim; Iain L Campbell
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

Review 10.  Transgenic models for cytokine-induced neurological disease.

Authors:  Iain L Campbell; Markus J Hofer; Axel Pagenstecher
Journal:  Biochim Biophys Acta       Date:  2009-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.